Atara Biotherapeutics, Inc.·4

Aug 20, 6:26 PM ET

Henrich Jill 4

4 · Atara Biotherapeutics, Inc. · Filed Aug 20, 2024

Insider Transaction Report

Form 4
Period: 2024-08-16
Henrich Jill
EVP, Chief Regulatory Officer
Transactions
  • Sale

    Common Stock

    2024-08-16$6.63/sh831$5,50920,510 total
  • Sale

    Common Stock

    2024-08-16$6.63/sh132$87520,378 total
Footnotes (3)
  • [F1]Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
  • [F2]The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2024 and August 19, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
  • [F3]This amount includes 4,284 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2024, and reflects the 1:25 reverse stock split effected by the Issuer on June 20, 2024.

Documents

1 file
  • 4
    form4.xmlPrimary